Biblio
“Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals.”, J Alzheimers Dis, vol. 49, no. 2, pp. 493-502, 2016.
, “Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 463-70, 2016.
, “Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse.”, J Alzheimers Dis, vol. 52, no. 1, pp. 243-69, 2016.
, “Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.”, J Alzheimers Dis, vol. 49, no. 1, pp. 93-100, 2016.
, “GSK-3β is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner.”, J Alzheimers Dis, vol. 49, no. 2, pp. 365-75, 2016.
, “Hierarchical Distribution of the Tau Cytoskeletal Pathology in the Thalamus of Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 49, no. 4, pp. 905-15, 2016.
, “Hyperactivity with Agitative-Like Behavior in a Mouse Tauopathy Model.”, J Alzheimers Dis, vol. 49, no. 3, pp. 783-95, 2016.
, “The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 2, pp. 547-60, 2016.
, “MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOEɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium.”, J Alzheimers Dis, vol. 49, no. 2, pp. 343-52, 2016.
, “Morroniside-Induced PP2A Activation Antagonizes Tau Hyperphosphorylation in a Cellular Model of Neurodegeneration.”, J Alzheimers Dis, vol. 51, no. 1, pp. 33-44, 2016.
, “Multifunctional Effect of Human Serum Albumin Reduces Alzheimer's Disease Related Pathologies in the 3xTg Mouse Model.”, J Alzheimers Dis, vol. 50, no. 1, pp. 175-88, 2016.
, “Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neurotoxicity.”, J Alzheimers Dis, vol. 51, no. 1, pp. 165-78, 2016.
, “Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention.”, J Alzheimers Dis, vol. 50, no. 3, pp. 779-89, 2016.
, “Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.”, J Alzheimers Dis, vol. 51, no. 2, pp. 339-43, 2016.
, “Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 3, pp. 765-78, 2016.
, “Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1099-109, 2016.
, “The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 345-56, 2016.
, “Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.”, J Alzheimers Dis, vol. 50, no. 2, pp. 539-46, 2016.
, “Puerarin Ameliorates D-Galactose Induced Enhanced Hippocampal Neurogenesis and Tau Hyperphosphorylation in Rat Brain.”, J Alzheimers Dis, vol. 51, no. 2, pp. 605-17, 2016.
, “Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1209-24, 2016.
, “Reversal of LTP-Like Cortical Plasticity in Alzheimer's Disease Patients with Tau-Related Faster Clinical Progression.”, J Alzheimers Dis, vol. 50, no. 2, pp. 605-16, 2016.
, “Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1179-87, 2016.
, “Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 69-79, 2016.
, “Spatial Navigation in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 1, pp. 77-90, 2016.
, “Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 271-6, 2016.
,